By 6 years , 51 % of patients ( CI , 42 % to 62 % ) allocated to ultralente insulin required additional short-acting insulin and 66 % of patients ( CI , 58 % to 73 % ) allocated to sulfonylurea required additional therapy with metformin or insulin to control symptoms and maintain fasting plasma glucose levels less than 15 mmol/L .
